Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
35 studies found for:    " December 22, 2010":" January 21, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
Rank Status Study
21 Completed
Has Results
Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients
Condition: HIV
Interventions: Drug: Tenofovir/emtricitabine;   Drug: Tenofovir/emtricitabine/efavirenz;   Drug: Raltegravir
22 Completed A Phase I, Open-label Trial to Explore the Pharmacokinetics, Safety and Tolerability of TMC278 (Rilpivirine) 25 mg Once Daily Following a 2-week Period Receiving Efavirenz, in Healthy Male and Female Volunteers
Condition: HIV
Interventions: Drug: TMC278;   Drug: Efavirenz
23 Withdrawn A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK2248761 Administered as an Oral Suspension to Healthy Adult Subjects
Condition: Infection, Human Immunodeficiency Virus
Intervention: Drug: 200mg [14C]- GSK2248761
24 Unknown  Compare to the Safety of Efavirenz and Nevirapine in Treating HIV Positive Patients With Mild Baseline Liver Function Test Impairment, and/or Hepatitis B or Hepatitis C Co-infection
Conditions: HIV Infections;   Liver Toxicity;   Hepatitis Co-infection
Intervention:
25 Completed Web-Based Middle School HIV Prevention Curricula: Aspiring for Reach and Impact
Conditions: HIV;   Sexually Transmitted Diseases
Intervention: Behavioral: It's Your Game Tech
26 Active, not recruiting TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Adults Coming From Any of the Three Ongoing Tibotec-Sponsored Studies With DRV
Condition: HIV-1 Infections
Interventions: Drug: Darunavir;   Drug: ritonavir
27 Active, not recruiting A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1
Condition: HIV-1 Infection
Intervention: Drug: Rilpivirine
28 Completed Safer Sex Intervention for Male Clients of Female Sex Workers in Tijuana, Mexico
Conditions: HIV;   Sexually Transmitted Diseases
Interventions: Behavioral: Hombre Seguro;   Behavioral: Didactic attention-control condition
29 Active, not recruiting High Risk Crack Use Settings and HIV in El Salvador
Conditions: HIV;   Sexually Transmitted Diseases
Interventions: Behavioral: Social Network HIV Testing;   Behavioral: Peer Network Intervention
30 Completed Metabolic Effects of Atazanavir/Ritonavir Versus Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine in naïve HIV-1 Infected Patients
Condition: HIV-1
Interventions: Drug: Darunavir / Ritonavir + Tenofovir / Emtricitabine;   Drug: Atazanavir / Ritonavir + Tenofovir / Emtricitabine
31 Withdrawn Project Wellness: Increasing HIV Testing Among West African Immigrants
Conditions: Diabetes;   Hypertension;   HIV
Interventions: Behavioral: HIV testing;   Behavioral: General Health Screen
32 Completed
Has Results
Study of Options for Second-Line Effective Combination Therapy (SELECT)
Condition: HIV-1 Infection
Interventions: Drug: Lopinavir/ritonavir;   Drug: Raltegravir;   Drug: Emtricitabine/tenofovir disoproxil fumarate;   Drug: Abacavir/lamivudine/zidovudine;   Drug: Abacavir/lamivudine;   Drug: Lamivudine/zidovudine;   Drug: Abacavir;   Drug: Zidovudine;   Drug: Lamivudine
33 Completed HIV/STI Prevention for Drug-Involved Couples
Condition: Sexually Transmitted Diseases
Interventions: Behavioral: Couple HIV/STI prevention intervention;   Behavioral: Couple-based HIV prevention;   Behavioral: Individual HIV/STI prevention;   Behavioral: Couple Wellness Promotion
34 Completed Male Tolerance Study of Dapivirine Gel Following Multiple Topical Penile Exposures
Condition: Topical Penile Exposures
Interventions: Drug: dapivirine;   Drug: matched placebo;   Drug: universal placebo
35 Unknown  Influence of Nevirapine on HCV Viral Load
Conditions: HCV Infection.;   HCV Viral Load.
Interventions: Drug: Nevirapine;   Drug: efavirenz, protease inhibitors

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-35) Next Page   
Study has passed its completion date and status has not been verified in more than two years.